Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates (CRY-NOT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03528915|
Recruitment Status : Completed
First Posted : May 18, 2018
Last Update Posted : January 23, 2019
|Condition or disease||Intervention/treatment|
|Ophthalmia Neonatorum||Other: Rifamycine treatment Other: whithout Rifamycine treatment|
|Study Type :||Observational|
|Actual Enrollment :||881 participants|
|Official Title:||Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT).|
|Actual Study Start Date :||September 9, 2015|
|Actual Primary Completion Date :||May 12, 2016|
|Actual Study Completion Date :||July 24, 2016|
Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
Other: Rifamycine treatment
Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
Other: whithout Rifamycine treatment
Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
- Occurrence of conjunctivitis during the first 8 days of life in newborns [ Time Frame: 8 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528915
|Amiens, France, 80054|